HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. HC Wainwright set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $6.17.
Shares of HTG Molecular Diagnostics (NASDAQ HTGM) opened at 2.61 on Monday. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25. The company’s market cap is $29.88 million. The company’s 50-day moving average price is $1.98 and its 200 day moving average price is $1.98.
HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). The firm had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.80 million. On average, analysts predict that HTG Molecular Diagnostics will post ($2.29) earnings per share for the current fiscal year.
In other news, major shareholder Holdings A/S Novo sold 80,586 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $2.07, for a total transaction of $166,813.02. Following the sale, the insider now directly owns 1,225,085 shares in the company, valued at approximately $2,535,925.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 1,660,944 shares of company stock worth $3,075,844 over the last 90 days. Corporate insiders own 7.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in HTGM. UBS Group AG purchased a new stake in shares of HTG Molecular Diagnostics during the 1st quarter valued at about $137,000. Two Sigma Securities LLC purchased a new stake in shares of HTG Molecular Diagnostics during the 1st quarter valued at about $150,000. Granahan Investment Management Inc. MA purchased a new stake in shares of HTG Molecular Diagnostics during the 1st quarter valued at about $228,000. Finally, Vanguard Group Inc. raised its position in shares of HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after buying an additional 37,841 shares in the last quarter. Hedge funds and other institutional investors own 21.69% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.